Abits
ABTS
Bakkt Holdings
BKKT
Riot Platforms
RIOT
Canaan
CAN
CATHEDRA BITCOIN INC
CBTTF
US Stock MarketDetailed Quotes
HLVX HilleVax
- 1.960
- -0.020-1.01%
Close Dec 13 16:00 ET
- 1.960
- 0.0000.00%
Post 16:20 ET
97.62MMarket Cap-0.63P/E (TTM)
1.990High1.950Low239.13KVolume1.990Open1.980Pre Close470.65KTurnover0.80%Turnover RatioLossP/E (Static)49.81MShares20.22052wk High0.53P/B58.65MFloat Cap1.55052wk Low--Dividend TTM29.92MShs Float24.420Historical High--Div YieldTTM2.02%Amplitude1.550Historical Low1.968Avg Price1Lot Size
Trending US Stocks
U.S. Crypto Concept Stocks U.S. Crypto Concept Stocks
Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data. Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data.
HilleVax Stock Forum
📊⚡️📊
On a day that saw its stock plummet by 84%, closing at $2.25, HilleVax, Inc. (Nasdaq: HLVX) announced the topline data results from its NEST-IN1 clinical study. This notable decline followed the announcement that the NEST-IN1 study did not meet its primary or secondary efficacy endpoints, leading the company to discontinue further dev...
HilleVax Reports Topline Data from NEST-IN1 Phase 2b Clinical Study of HIL-214 in Infants
HilleVax announced topline results from the NEST-IN1 Phase 2b study of HIL-214 in infants. The trial, conducted in the US and Latin America, did not meet its primary or secondary efficacy endpoints. Specifically, the vaccine showed a mere 5% efficacy against moderate or severe acute gastroenteritis caused by norovirus, which was statistically insignificant. Consequently, HilleVax wil...
No comment yet